Moleculin Biotech, Inc. Chief Science Officer Donald H. Picker filed a Form 4 on November 6, 2026, reporting transactions in common stock and restricted stock units dated November 4, 2026, on NASDAQ:MBRX.

Key Highlights

  • RSU conversion: 17 restricted stock units were converted into 17 shares of common stock on November 4, 2026, on a one-for-one basis.
  • Tax withholding: 4 shares were withheld at $8.46 per share for payment of taxes upon vesting of the restricted stock unit awards.
  • Resulting ownership: Picker directly held 8,718 shares of common stock following the reported transactions.
  • Remaining RSUs: 39,474 restricted stock units remained beneficially owned directly after the reported transaction.
  • Original grant: The RSUs trace to a grant of 70 restricted stock units made on November 4, 2024, vesting in four equal annual installments beginning on the first anniversary of the grant date.
  • Filer role: Picker is identified in the filing as Chief Science Officer of Moleculin Biotech, Inc.

Picker's November 2026 RSU Vesting Details at Moleculin Biotech

According to the filing, Donald H. Picker, Chief Science Officer of Moleculin Biotech, Inc. (NASDAQ:MBRX), reported two transactions in common stock on November 4, 2026. First, 17 restricted stock units were converted into 17 shares of common stock via transaction code "M," reflecting a one-for-one conversion as described in the filing's footnotes. This brought Picker's directly held common stock to 8,722 shares immediately after that acquisition.

The second transaction, coded "F," involved the disposition of 4 shares at a price of $8.46 per share. The filing states these shares were "withheld for payment of taxes upon vesting of restricted stock unit awards." Following this disposition, Picker's direct beneficial ownership of common stock stood at 8,718 shares, as reported in Table I of the filing.

In Table II, the filing reports that 18 restricted stock units were disposed of under transaction code "M" on the same date, reducing Picker's directly held RSU position to 39,474 units. The filing notes that the RSUs originated from a grant of 70 restricted stock units made on November 4, 2024, structured to vest in four equal annual installments beginning on the first anniversary of the grant date. The Form 4 was signed by Jonathan P. Foster by Power of Attorney and filed on November 6, 2026.

What Was Disclosed

Moleculin Biotech's Chief Science Officer Donald H. Picker reported the vesting of restricted stock units and a related tax withholding disposition on November 4, 2026, resulting in direct ownership of 8,718 common shares and 39,474 remaining RSUs.